Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All probiotics studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchProbioticsProbiotics (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Case 78% Improvement Relative Risk Probiotics for COVID-19  Di Pierro et al.  Prophylaxis Do probiotics reduce COVID-19 infections? Retrospective 287 patients in Italy (January - March 2022) Fewer cases with probiotics (p=0.0074) c19early.org Di Pierro et al., Minerva Medica, September 2023 Favors probiotics Favors control

Role of S. salivarius K12 in the prevention of URTI and AGE in nursery-aged children

Di Pierro et al., Minerva Medica, doi:10.23736/S0026-4806.23.08920-6, NCT05840926
Sep 2023  
  Post
  Facebook
Share
  Source   PDF   All   Meta
Probiotics for COVID-19
18th treatment shown to reduce risk in March 2021
 
*, now known with p = 0.0000013 from 26 studies.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
3,800+ studies for 60+ treatments. c19early.org
Retrospective study of 287 nursery school children in Italy, 186 treated with S. salivarius K12 probiotic. The probiotic group had significantly lower rates of COVID-19, bronchitis, sinusitis, and laryngitis as well as lower antibiotic use. The study was registered retrospectively and details of COVID-19 diagnosis are not provided. Parents that administer the treatment may also use other treatments or take other actions that reduce risk for their children.
The immune effects of probiotics are strain-specific.
risk of case, 77.8% lower, RR 0.22, p = 0.007, treatment mean 0.02 (±0.15) n=186, control mean 0.09 (±0.29) n=101.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Di Pierro et al., 30 Sep 2023, retrospective, Italy, peer-reviewed, 10 authors, study period January 2022 - March 2022, trial NCT05840926 (history). Contact: f.dipierro@vellejaresearch.com.
This PaperProbioticsAll
Abstract: © This document is protected by international copyright laws. No additional reproduction is authorized. It is permitted for personal use to download and save only one file and print only one copy of this Article. It is not permitted to make additional copies (either sporadically or systematically, either printed or electronic) of the Article for any purpose. It is not permitted to distribute the electronic copy of the article through online internet and/or intranet file sharing systems, electronic mailing or any other means which may allow access to the Article. The use of all or any part of the Article for any Commercial Use is not permitted. The creation of derivative works from the Article is not permitted. The production of reprints for personal or commercial use is not permitted. It is not permitted to remove, cover, overlay, obscure, block, or change any copyright notices or terms of use which the Publisher may post on the Article. It is not permitted to frame or use framing techniques to enclose any trademark, logo, or other proprietary information of the Publisher. COPYRIGHT 2023 EDIZIONI MINERVA MEDICA LETTERS TO THE EDITOR © 2023 ediZiONi MiNerVa Medica Online version at https://www.minervamedica.it Minerva Medica 2023 Sep 28 dOi: 10.23736/S0026-4806.23.08920-6 role of S. salivarius K12 in the prevention of UrTi and aGe in nursery-aged children acute upper respiratory tract infections (UrTis) in children are a major cause of morbidity, absence from daily life and are among the most common reasons for pediatrician visits.1, 2 any intervention that could prevent them would deliver important life-saving and costeffective impacts. despite their wide clinical use, the evidence-based indications of probiotics are narrow and mostly focus on the treatment of acute gastroenteritis (aGe).3 indeed, the potential ability of probiotics to influence and stabilize the gut microbiota, improving its resistance to colonization, supports their rational use.4 although the evidence for ability of probiotics to also modulate immune functions is thought to be modest, it should nonetheless make the case for probiotics to play a possible role in preventing and/or reducing the symptoms of upper respiratory diseases.5 To date, strains from Lactobacillus and Bifidobacterium spp. are the most common probiotics used to treat a wide range of diseases, ailments and conditions that affect humans and animals.6 Much less common is the possibility of resorting to different bacterial species, such as Enterococcus faecium, endowed with well-documented clinical anti-UrTi and anti-aGe properties.7 among the species less widely used as probiotics, the oral commensal Streptococcus salivarius (Ss) is among the best studied, with particular reference to the K12 strain.8 This strain has been widely investigated, especially for its effective action in fighting ear, oral, pharyngeal, and tonsillar infections caused by S. pyogenes, S. pneumoniae, M. catarrhalis, and/or H. influenzae.9 The effectiveness of the Ss K12 is more commonly traced back to its ability to release two antibiotics (Salivaricin a2 and Salivaricin B), which are effective at damaging the membrane of the target bacteria.10 However, the capacity of Ss K12 to counteract bacterial antagonists is not limited to the release of bacteriocins. Other microbial species, nonsensitive to salivaricins a2 and B, including oral-pharyngeal viruses (syncytial virus, adenovirus, rhinovirus), fungi such as Candida, or..
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit